5 completed, 4 no longer available, 1 approved for marketing. 3 Phase 2, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 2 | Completed 2 |
| Not applicable | 1 | Completed 1 |
Follow 3,4-diaminopyridine: new trials by email Literature Review of 3,4-diaminopyridine trials Research Report on 3,4-diaminopyridine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome Continuous 3,4-DAP, Taper 3,4-DAP to Placebo - Lambert-Eaton Myasthenic Syndrome, Eaton-Lambert Myasthenic Syndrome | Phase 2 | Completed | Jacobus Pharmaceutical | 32 | 2012-01-01 | 2017-07-11 |
| Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism 3,4-diaminopyridine - Botulism | Phase 2 / Phase 3 | Completed | Centre Hospitalier Universitaire, Amiens | 3 | 2011-09-01 | 2025-09-19 |
| Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation 3,4-diaminopyridine, Placebo - Multiple Sclerosis, Fatigue | Phase 2 | Completed | University of Aarhus | 120 | 2006-06-01 | 2007-12-17 |
| Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP 3,4-diaminopyridine - Lambert Eaton Myasthenic Syndrome (LEMS) | No longer available | Louis H. Weimer, MD | 2005-05-01 | 2013-07-18 | ||
| Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis 3,4-diaminopyridine - Multiple Sclerosis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 126 | 2005-02-01 | 2011-02-21 |
| Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome 3,4-diaminopyridine - Lambert-Eaton Myasthenic Syndrome | Not applicable | Completed | FDA Office of Orphan Products Development | 26 | 1994-08-01 | 2015-03-25 |
| Treatment Use of 3,4-Diaminopyridine 3,4-diaminopyridine - Myasthenic Syndromes, Congenital | No longer available | Vern C. Juel, M.D. | 2025-01-20 | |||
| 3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS) 3,4-DIAMINOPYRIDINE - Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndrome | Approved for marketing | Lahey Clinic | 2022-04-11 | |||
| 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM) 3,4-diaminopyridine - Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenia (CM) | No longer available | Oregon Health and Science University | 2019-12-11 | |||
| Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia 3,4-Diaminopyridine - Congenital Myasthenic Syndrome | No longer available | Ricardo Maselli | 2023-06-02 |
Lambert-Eaton Myasthenic Syndrome (5) · Myasthenic Syndromes, Congenital (4) · Fatigue (2) · Multiple Sclerosis (2) · Botulism (1) · Mental Disorders (1) · Neurologic Manifestations (1) · Rare Diseases (1)
Assistance Publique - Hôpitaux de Paris (1) · Centre Hospitalier Universitaire, Amiens (1) · FDA Office of Orphan Products Development (1) · Jacobus Pharmaceutical (1) · Lahey Clinic (1) · Louis H. Weimer, MD (1) · Oregon Health and Science University (1) · Ricardo Maselli (1) · University of Aarhus (1) · Vern C. Juel, M.D. (1)
United States (6) · France (2) · Denmark (1)
Donald B. Sanders (1) · Henning Andersen, MD, DMSc (1) · Jayashri Srinivasan, MD,MCRP,PhD (1) · Johannes Jacobsen, Professor (1) · Louis H Weimer, MD (1) · Pierre Cesaro, MD (1) · Ricardo Maselli, MD (1) · Vern C. Juel, M.D. (1)